Share Price and Basic Stock Data
Last Updated: February 6, 2026, 2:30 pm
| PEG Ratio | -8.77 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aster DM Healthcare Ltd operates in the Hospitals & Medical Services sector, focusing on providing healthcare services across various formats. As of the latest reporting, the company’s share price stood at ₹558, with a market capitalization of ₹28,911 Cr. The revenue trends indicate fluctuations, with sales recorded at ₹2,994 Cr for the fiscal year ending March 2023, followed by an increase to ₹3,699 Cr for March 2024, and projected to reach ₹4,138 Cr for March 2025. The trailing twelve months (TTM) revenue was ₹4,325 Cr, showing a steady upward trajectory. Quarterly sales have also displayed growth, rising from ₹807 Cr in March 2023 to ₹929 Cr in September 2023. This growth trajectory reflects the company’s ability to adapt to market conditions and expand its service offerings, positioning itself favorably against sector peers, where average growth rates typically range from 5% to 15% annually.
Profitability and Efficiency Metrics
The profitability metrics of Aster DM Healthcare reflect a mixed performance. The operating profit margin (OPM) has gradually improved from 11% in September 2022 to 20% by September 2025, indicating enhanced operational efficiency. The net profit for the fiscal year ending March 2023 was ₹475 Cr, which is expected to rise significantly to ₹5,408 Cr by March 2025. This shift is complemented by a remarkable EPS increase from ₹8.51 in March 2023 to ₹107.98 in March 2025. However, the company reported a low return on equity (ROE) of 8.26% and return on capital employed (ROCE) of 10.7%, which are below the typical industry benchmarks, suggesting room for improvement. The interest coverage ratio (ICR) of 7.37x provides a comfortable buffer against debt servicing, indicating solid earnings relative to interest obligations.
Balance Sheet Strength and Financial Ratios
Aster DM Healthcare’s balance sheet reveals a total borrowings figure of ₹2,089 Cr, against reserves of ₹4,015 Cr, showcasing a healthy reserves-to-borrowings ratio. The company’s total liabilities stood at ₹7,808 Cr, with total assets of ₹7,808 Cr, indicating a balanced financial structure. The debt-to-equity ratio at 0.18x suggests low leverage, which is favorable in the capital-intensive healthcare sector. The current ratio of 2.16x indicates strong liquidity, surpassing the typical sector norm of around 1.5x, ensuring that the company can meet its short-term obligations. However, the book value per share has decreased to ₹68.63 in March 2025 from ₹100.70 in March 2024, reflecting potential asset impairment or valuation adjustments. The price-to-book value (P/BV) ratio of 7.06x indicates that the stock is trading at a premium, which may concern value-focused investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aster DM Healthcare indicates a diverse ownership structure that includes promoters holding 40.39%, foreign institutional investors (FIIs) at 18.72%, domestic institutional investors (DIIs) at 26.32%, and the public at 14.33%. The promoter holding has remained relatively stable, indicating consistent confidence from the founding members in the company’s future. Institutional participation is robust, with DIIs increasing their stake from 8.93% in December 2022 to 26.32% in September 2025, reflecting growing investor confidence. Conversely, FII holdings have decreased from 42.49% in December 2022 to 18.72% in September 2025, which may suggest a shift in foreign investor sentiment. The total number of shareholders has also decreased from 84,573 in December 2022 to 147,304 in September 2025, indicating a consolidation of ownership as larger investors accumulate shares.
Outlook, Risks, and Final Insight
The outlook for Aster DM Healthcare appears cautiously optimistic, driven by strong revenue growth and improving profitability metrics. However, potential risks include the company’s low ROE and ROCE, which may hinder its ability to attract new investments. Additionally, the volatility in quarterly sales and net profit, particularly the dip to a loss of ₹15 Cr in September 2023, raises concerns about operational consistency. Furthermore, the declining FII participation could impact stock liquidity and investor sentiment. Should the company continue on its path of improving operational efficiencies and sustain revenue growth, it may solidify its position in the healthcare sector. Conversely, any adverse regulatory changes or economic downturns could pose significant challenges. Stakeholders must weigh these factors when considering future investments in Aster DM Healthcare.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.6 Cr. | 136 | 187/120 | 9.30 | 117 | 2.57 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 15.4 Cr. | 14.6 | 33.0/14.6 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.8 Cr. | 10.4 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 103 Cr. | 54.9 | 98.7/52.2 | 22.7 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 18.6 Cr. | 3.44 | 6.42/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 25,443.14 Cr | 680.57 | 87.86 | 92.86 | 0.36% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,192 | 807 | 841 | 929 | 955 | 974 | 1,002 | 1,086 | 1,050 | 1,000 | 1,078 | 1,197 | 1,186 |
| Expenses | 2,743 | 687 | 722 | 787 | 805 | 817 | 841 | 869 | 864 | 818 | 876 | 961 | 983 |
| Operating Profit | 449 | 120 | 119 | 142 | 149 | 156 | 161 | 217 | 186 | 182 | 202 | 236 | 202 |
| OPM % | 14% | 15% | 14% | 15% | 16% | 16% | 16% | 20% | 18% | 18% | 19% | 20% | 17% |
| Other Income | 10 | 149 | -17 | -64 | 153 | -40 | 5,120 | 35 | 9 | 5 | 29 | 28 | -0 |
| Interest | 87 | 25 | 25 | 30 | 25 | 30 | 29 | 31 | 31 | 32 | 31 | 31 | 31 |
| Depreciation | 198 | 54 | 51 | 54 | 57 | 58 | 60 | 62 | 62 | 64 | 63 | 66 | 68 |
| Profit before tax | 173 | 190 | 26 | -7 | 220 | 28 | 5,191 | 159 | 102 | 91 | 136 | 167 | 103 |
| Tax % | 8% | 4% | 24% | 120% | 5% | 108% | 1% | 33% | 37% | 6% | 31% | 27% | 43% |
| Net Profit | 159 | 183 | 20 | -15 | 209 | -2 | 5,152 | 106 | 64 | 86 | 94 | 121 | 59 |
| EPS in Rs | 2.79 | 3.42 | 0.10 | -0.62 | 3.59 | -0.48 | 103.00 | 1.94 | 1.14 | 1.58 | 1.65 | 2.12 | 1.01 |
Last Updated: February 6, 2026, 3:46 pm
Below is a detailed analysis of the quarterly data for Aster DM Healthcare Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 1,186.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,197.00 Cr. (Sep 2025) to 1,186.00 Cr., marking a decrease of 11.00 Cr..
- For Expenses, as of Dec 2025, the value is 983.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 961.00 Cr. (Sep 2025) to 983.00 Cr., marking an increase of 22.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 202.00 Cr.. The value appears to be declining and may need further review. It has decreased from 236.00 Cr. (Sep 2025) to 202.00 Cr., marking a decrease of 34.00 Cr..
- For OPM %, as of Dec 2025, the value is 17.00%. The value appears to be declining and may need further review. It has decreased from 20.00% (Sep 2025) to 17.00%, marking a decrease of 3.00%.
- For Other Income, as of Dec 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Sep 2025) to 0.00 Cr., marking a decrease of 28.00 Cr..
- For Interest, as of Dec 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 31.00 Cr..
- For Depreciation, as of Dec 2025, the value is 68.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 66.00 Cr. (Sep 2025) to 68.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 103.00 Cr.. The value appears to be declining and may need further review. It has decreased from 167.00 Cr. (Sep 2025) to 103.00 Cr., marking a decrease of 64.00 Cr..
- For Tax %, as of Dec 2025, the value is 43.00%. The value appears to be increasing, which may not be favorable. It has increased from 27.00% (Sep 2025) to 43.00%, marking an increase of 16.00%.
- For Net Profit, as of Dec 2025, the value is 59.00 Cr.. The value appears to be declining and may need further review. It has decreased from 121.00 Cr. (Sep 2025) to 59.00 Cr., marking a decrease of 62.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 1.01. The value appears to be declining and may need further review. It has decreased from 2.12 (Sep 2025) to 1.01, marking a decrease of 1.11.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,871 | 3,876 | 5,250 | 5,931 | 6,721 | 7,963 | 8,652 | 8,608 | 10,253 | 2,994 | 3,699 | 4,138 | 4,325 |
| Expenses | 2,421 | 3,370 | 4,805 | 5,582 | 6,089 | 6,886 | 7,187 | 7,506 | 8,720 | 2,547 | 3,124 | 3,384 | 3,520 |
| Operating Profit | 451 | 506 | 445 | 349 | 632 | 1,077 | 1,465 | 1,103 | 1,533 | 447 | 575 | 754 | 805 |
| OPM % | 16% | 13% | 8% | 6% | 9% | 14% | 17% | 13% | 15% | 15% | 16% | 18% | 19% |
| Other Income | 19 | 23 | 25 | 453 | 177 | -155 | -158 | 53 | 51 | 353 | 32 | 5,169 | 71 |
| Interest | 48 | 79 | 189 | 371 | 204 | 205 | 391 | 334 | 307 | 96 | 119 | 133 | 125 |
| Depreciation | 111 | 144 | 243 | 322 | 298 | 306 | 586 | 618 | 641 | 192 | 220 | 249 | 256 |
| Profit before tax | 310 | 306 | 38 | 108 | 308 | 410 | 330 | 205 | 637 | 511 | 268 | 5,542 | 496 |
| Tax % | 9% | 11% | 78% | 10% | 8% | 10% | 5% | 13% | 6% | 7% | 21% | 2% | |
| Net Profit | 284 | 272 | 8 | 98 | 282 | 367 | 315 | 178 | 601 | 475 | 212 | 5,408 | 365 |
| EPS in Rs | 4.69 | 7.00 | 0.20 | 2.52 | 5.32 | 6.59 | 5.54 | 2.96 | 10.53 | 8.51 | 2.59 | 107.66 | 6.49 |
| Dividend Payout % | 35% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 4,637% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -4.23% | -97.06% | 1125.00% | 187.76% | 30.14% | -14.17% | -43.49% | 237.64% | -20.97% | -55.37% | 2450.94% |
| Change in YoY Net Profit Growth (%) | 0.00% | -92.83% | 1222.06% | -937.24% | -157.61% | -44.31% | -29.32% | 281.13% | -258.61% | -34.40% | 2506.31% |
Aster DM Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -14% |
| 3 Years: | -26% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -7% |
| 3 Years: | -17% |
| TTM: | 82% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 38% |
| 3 Years: | 38% |
| 1 Year: | 56% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 8% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: December 4, 2025, 12:59 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 375 | 389 | 403 | 403 | 505 | 505 | 497 | 497 | 500 | 500 | 500 | 500 | 518 |
| Reserves | 536 | 1,096 | 17 | 1,472 | 2,327 | 2,709 | 2,775 | 2,875 | 3,080 | 3,574 | 3,686 | 2,554 | 4,015 |
| Borrowings | 886 | 1,091 | 3,321 | 2,758 | 2,352 | 2,788 | 5,605 | 4,804 | 5,282 | 6,075 | 1,758 | 2,392 | 2,089 |
| Other Liabilities | 1,097 | 1,834 | 2,003 | 2,171 | 2,296 | 2,926 | 3,528 | 3,444 | 3,661 | 4,687 | 12,039 | 1,154 | 1,186 |
| Total Liabilities | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,983 | 6,600 | 7,808 |
| Fixed Assets | 1,087 | 2,237 | 2,507 | 3,520 | 3,738 | 4,289 | 7,124 | 6,749 | 7,009 | 9,052 | 3,175 | 3,920 | 4,024 |
| CWIP | 357 | 197 | 358 | 290 | 402 | 550 | 736 | 934 | 998 | 279 | 170 | 293 | 401 |
| Investments | 7 | 3 | 39 | 32 | 38 | 22 | 34 | 63 | 45 | 80 | 17 | 245 | 1,184 |
| Other Assets | 1,442 | 1,972 | 2,839 | 2,962 | 3,302 | 4,067 | 4,511 | 3,874 | 4,470 | 5,425 | 14,620 | 2,142 | 2,199 |
| Total Assets | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,983 | 6,600 | 7,808 |
Below is a detailed analysis of the balance sheet data for Aster DM Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 518.00 Cr.. The value appears strong and on an upward trend. It has increased from 500.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 18.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,015.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,554.00 Cr. (Mar 2025) to 4,015.00 Cr., marking an increase of 1,461.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,089.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,392.00 Cr. (Mar 2025) to 2,089.00 Cr., marking a decrease of 303.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,186.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,154.00 Cr. (Mar 2025) to 1,186.00 Cr., marking an increase of 32.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 7,808.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,600.00 Cr. (Mar 2025) to 7,808.00 Cr., marking an increase of 1,208.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4,024.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,920.00 Cr. (Mar 2025) to 4,024.00 Cr., marking an increase of 104.00 Cr..
- For CWIP, as of Sep 2025, the value is 401.00 Cr.. The value appears strong and on an upward trend. It has increased from 293.00 Cr. (Mar 2025) to 401.00 Cr., marking an increase of 108.00 Cr..
- For Investments, as of Sep 2025, the value is 1,184.00 Cr.. The value appears strong and on an upward trend. It has increased from 245.00 Cr. (Mar 2025) to 1,184.00 Cr., marking an increase of 939.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,199.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,142.00 Cr. (Mar 2025) to 2,199.00 Cr., marking an increase of 57.00 Cr..
- For Total Assets, as of Sep 2025, the value is 7,808.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,600.00 Cr. (Mar 2025) to 7,808.00 Cr., marking an increase of 1,208.00 Cr..
Notably, the Reserves (4,015.00 Cr.) exceed the Borrowings (2,089.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -435.00 | 505.00 | 442.00 | 347.00 | 630.00 | -1.00 | -4.00 | -3.00 | -4.00 | 441.00 | 574.00 | 752.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 86 | 83 | 93 | 79 | 84 | 93 | 100 | 86 | 72 | 285 | 23 | 23 |
| Inventory Days | 71 | 93 | 92 | 102 | 111 | 110 | 138 | 122 | 129 | 612 | 44 | 36 |
| Days Payable | 176 | 178 | 187 | 151 | 150 | 153 | 303 | 290 | 267 | 1,400 | 183 | 166 |
| Cash Conversion Cycle | -18 | -2 | -1 | 30 | 45 | 50 | -65 | -83 | -66 | -503 | -116 | -107 |
| Working Capital Days | 61 | 69 | 68 | 6 | 59 | 28 | 8 | 5 | 5 | -21 | 272 | -32 |
| ROCE % | 18% | 14% | 6% | 1% | 7% | 13% | 12% | 6% | 10% | 3% | 4% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 23,927,134 | 3.91 | 1475.95 | N/A | N/A | N/A |
| Kotak Small Cap Fund | 11,757,234 | 4.2 | 725.25 | N/A | N/A | N/A |
| Quant Small Cap Fund | 11,305,160 | 2.34 | 697.36 | 1,758,485 | 2025-12-08 07:20:44 | 542.89% |
| Nippon India Small Cap Fund | 9,522,707 | 0.86 | 587.41 | N/A | N/A | N/A |
| SBI Contra Fund | 9,199,605 | 1.14 | 567.48 | N/A | N/A | N/A |
| Kotak Midcap Fund | 6,423,124 | 0.65 | 396.21 | 6,137,365 | 2026-01-26 00:42:09 | 4.66% |
| Franklin India Small Cap Fund | 4,675,704 | 2.18 | 288.42 | 5,618,134 | 2025-12-15 01:26:06 | -16.77% |
| HDFC Childrens Fund | 3,759,174 | 2.18 | 231.88 | N/A | N/A | N/A |
| HSBC Small Cap Fund | 3,574,000 | 1.38 | 220.46 | N/A | N/A | N/A |
| Franklin India Mid Cap Fund | 2,407,002 | 1.16 | 148.48 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 107.98 | 2.60 | 8.54 | 10.58 | 2.97 |
| Diluted EPS (Rs.) | 107.85 | 2.60 | 8.53 | 10.57 | 2.97 |
| Cash EPS (Rs.) | 113.62 | 8.87 | 25.12 | 24.96 | 15.93 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 68.63 | 100.70 | 89.81 | 90.15 | 77.14 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 68.63 | 100.70 | 89.81 | 90.15 | 77.14 |
| Revenue From Operations / Share (Rs.) | 82.85 | 74.05 | 238.89 | 206.21 | 173.19 |
| PBDIT / Share (Rs.) | 18.27 | 12.07 | 32.90 | 30.85 | 22.39 |
| PBIT / Share (Rs.) | 13.29 | 7.66 | 17.28 | 17.97 | 9.96 |
| PBT / Share (Rs.) | 9.81 | 5.46 | 10.69 | 12.80 | 4.05 |
| Net Profit / Share (Rs.) | 108.64 | 4.46 | 9.49 | 12.08 | 3.51 |
| NP After MI And SOA / Share (Rs.) | 107.66 | 2.59 | 8.51 | 10.58 | 2.97 |
| PBDIT Margin (%) | 22.05 | 16.29 | 13.77 | 14.96 | 12.92 |
| PBIT Margin (%) | 16.04 | 10.34 | 7.23 | 8.71 | 5.75 |
| PBT Margin (%) | 11.83 | 7.36 | 4.47 | 6.20 | 2.34 |
| Net Profit Margin (%) | 131.13 | 6.02 | 3.97 | 5.85 | 2.02 |
| NP After MI And SOA Margin (%) | 129.94 | 3.49 | 3.56 | 5.12 | 1.71 |
| Return on Networth / Equity (%) | 156.87 | 2.83 | 10.43 | 13.30 | 4.38 |
| Return on Capital Employeed (%) | 11.59 | 5.71 | 8.44 | 9.93 | 5.86 |
| Return On Assets (%) | 81.40 | 0.71 | 2.85 | 4.19 | 1.26 |
| Long Term Debt / Equity (X) | 0.14 | 0.09 | 0.32 | 0.37 | 0.52 |
| Total Debt / Equity (X) | 0.18 | 0.14 | 0.56 | 0.55 | 0.56 |
| Asset Turnover Ratio (%) | 0.33 | 0.22 | 0.18 | 0.14 | 0.09 |
| Current Ratio (X) | 2.16 | 1.25 | 1.06 | 1.15 | 1.14 |
| Quick Ratio (X) | 2.06 | 1.25 | 0.77 | 0.86 | 0.86 |
| Inventory Turnover Ratio (X) | 40.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 114.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 109.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | -14.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | -9.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 7.37 | 5.46 | 4.99 | 5.97 | 3.79 |
| Interest Coverage Ratio (Post Tax) (X) | 4.28 | 2.96 | 2.44 | 3.34 | 1.59 |
| Enterprise Value (Cr.) | 23702.29 | 21464.85 | 14334.72 | 12129.54 | 8918.86 |
| EV / Net Operating Revenue (X) | 5.73 | 5.80 | 1.20 | 1.18 | 1.04 |
| EV / EBITDA (X) | 25.97 | 35.61 | 8.72 | 7.91 | 8.02 |
| MarketCap / Net Operating Revenue (X) | 5.85 | 5.53 | 1.01 | 0.95 | 0.79 |
| Retention Ratios (%) | -14.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 7.06 | 4.48 | 2.96 | 2.48 | 2.02 |
| Price / Net Operating Revenue (X) | 5.85 | 5.53 | 1.01 | 0.95 | 0.79 |
| EarningsYield | 0.22 | 0.01 | 0.03 | 0.05 | 0.02 |
After reviewing the key financial ratios for Aster DM Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 107.98. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 107.98, marking an increase of 105.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is 107.85. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 107.85, marking an increase of 105.25.
- For Cash EPS (Rs.), as of Mar 25, the value is 113.62. This value is within the healthy range. It has increased from 8.87 (Mar 24) to 113.62, marking an increase of 104.75.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.63. It has decreased from 100.70 (Mar 24) to 68.63, marking a decrease of 32.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.63. It has decreased from 100.70 (Mar 24) to 68.63, marking a decrease of 32.07.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 82.85. It has increased from 74.05 (Mar 24) to 82.85, marking an increase of 8.80.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 18.27. This value is within the healthy range. It has increased from 12.07 (Mar 24) to 18.27, marking an increase of 6.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.29. This value is within the healthy range. It has increased from 7.66 (Mar 24) to 13.29, marking an increase of 5.63.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.81. This value is within the healthy range. It has increased from 5.46 (Mar 24) to 9.81, marking an increase of 4.35.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 108.64. This value is within the healthy range. It has increased from 4.46 (Mar 24) to 108.64, marking an increase of 104.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 107.66. This value is within the healthy range. It has increased from 2.59 (Mar 24) to 107.66, marking an increase of 105.07.
- For PBDIT Margin (%), as of Mar 25, the value is 22.05. This value is within the healthy range. It has increased from 16.29 (Mar 24) to 22.05, marking an increase of 5.76.
- For PBIT Margin (%), as of Mar 25, the value is 16.04. This value is within the healthy range. It has increased from 10.34 (Mar 24) to 16.04, marking an increase of 5.70.
- For PBT Margin (%), as of Mar 25, the value is 11.83. This value is within the healthy range. It has increased from 7.36 (Mar 24) to 11.83, marking an increase of 4.47.
- For Net Profit Margin (%), as of Mar 25, the value is 131.13. This value exceeds the healthy maximum of 10. It has increased from 6.02 (Mar 24) to 131.13, marking an increase of 125.11.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 129.94. This value exceeds the healthy maximum of 20. It has increased from 3.49 (Mar 24) to 129.94, marking an increase of 126.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 156.87. This value is within the healthy range. It has increased from 2.83 (Mar 24) to 156.87, marking an increase of 154.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.59. This value is within the healthy range. It has increased from 5.71 (Mar 24) to 11.59, marking an increase of 5.88.
- For Return On Assets (%), as of Mar 25, the value is 81.40. This value is within the healthy range. It has increased from 0.71 (Mar 24) to 81.40, marking an increase of 80.69.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 0.2. It has increased from 0.09 (Mar 24) to 0.14, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has increased from 0.14 (Mar 24) to 0.18, marking an increase of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.33. It has increased from 0.22 (Mar 24) to 0.33, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 25, the value is 2.16. This value is within the healthy range. It has increased from 1.25 (Mar 24) to 2.16, marking an increase of 0.91.
- For Quick Ratio (X), as of Mar 25, the value is 2.06. This value exceeds the healthy maximum of 2. It has increased from 1.25 (Mar 24) to 2.06, marking an increase of 0.81.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 40.80. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 40.80, marking an increase of 40.80.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 114.80. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 114.80, marking an increase of 114.80.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 109.73. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 109.73, marking an increase of 109.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is -14.80. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -14.80, marking a decrease of 14.80.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is -9.73. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -9.73, marking a decrease of 9.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.37. This value is within the healthy range. It has increased from 5.46 (Mar 24) to 7.37, marking an increase of 1.91.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.28. This value is within the healthy range. It has increased from 2.96 (Mar 24) to 4.28, marking an increase of 1.32.
- For Enterprise Value (Cr.), as of Mar 25, the value is 23,702.29. It has increased from 21,464.85 (Mar 24) to 23,702.29, marking an increase of 2,237.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.73. This value exceeds the healthy maximum of 3. It has decreased from 5.80 (Mar 24) to 5.73, marking a decrease of 0.07.
- For EV / EBITDA (X), as of Mar 25, the value is 25.97. This value exceeds the healthy maximum of 15. It has decreased from 35.61 (Mar 24) to 25.97, marking a decrease of 9.64.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.85. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 5.85, marking an increase of 0.32.
- For Retention Ratios (%), as of Mar 25, the value is -14.80. This value is below the healthy minimum of 30. It has decreased from 0.00 (Mar 24) to -14.80, marking a decrease of 14.80.
- For Price / BV (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 4.48 (Mar 24) to 7.06, marking an increase of 2.58.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.85. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 5.85, marking an increase of 0.32.
- For EarningsYield, as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.22, marking an increase of 0.21.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aster DM Healthcare Ltd:
- Net Profit Margin: 131.13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.59% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 156.87% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.28
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.06
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 80.9 (Industry average Stock P/E: 87.86)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.18
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 131.13%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Bengaluru Kerala 560027 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Azad Moopen | Founder Chairman & Mng. Director |
| Ms. Alisha Moopen | Deputy Managing Director |
| Mr. Daniel Robert Mintz | Non Executive Director |
| Mr. T J Wilson | Non Executive Director |
| Mr. Shamsudheen Bin Mohideen Mammu Haji | Non Executive Director |
| Dr. Zeba Azad Moopen | Non Executive Director |
| Mr. Anoop Moopen | Non Executive Director |
| Ms. Purana Housdurgamvijaya Deepti | Independent Director |
| Mr. Chenayappillil John George | Independent Director |
| Mr. Maniedath Madhavan Nambiar | Independent Director |
| Mr. Sunil Theckath Vasudevan | Independent Director |
| Dr. James Mathew | Independent Director |
| Mr. Emmanuel David Gootam | Independent Director |
FAQ
What is the intrinsic value of Aster DM Healthcare Ltd?
Aster DM Healthcare Ltd's intrinsic value (as of 06 February 2026) is ₹428.47 which is 23.76% lower the current market price of ₹562.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹29,116 Cr. market cap, FY2025-2026 high/low of ₹732/386, reserves of ₹4,015 Cr, and liabilities of ₹7,808 Cr.
What is the Market Cap of Aster DM Healthcare Ltd?
The Market Cap of Aster DM Healthcare Ltd is 29,116 Cr..
What is the current Stock Price of Aster DM Healthcare Ltd as on 06 February 2026?
The current stock price of Aster DM Healthcare Ltd as on 06 February 2026 is ₹562.
What is the High / Low of Aster DM Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aster DM Healthcare Ltd stocks is ₹732/386.
What is the Stock P/E of Aster DM Healthcare Ltd?
The Stock P/E of Aster DM Healthcare Ltd is 80.9.
What is the Book Value of Aster DM Healthcare Ltd?
The Book Value of Aster DM Healthcare Ltd is 87.5.
What is the Dividend Yield of Aster DM Healthcare Ltd?
The Dividend Yield of Aster DM Healthcare Ltd is 0.91 %.
What is the ROCE of Aster DM Healthcare Ltd?
The ROCE of Aster DM Healthcare Ltd is 10.7 %.
What is the ROE of Aster DM Healthcare Ltd?
The ROE of Aster DM Healthcare Ltd is 8.26 %.
What is the Face Value of Aster DM Healthcare Ltd?
The Face Value of Aster DM Healthcare Ltd is 10.0.